Erbolato E B, da Silva E V, Miguel O, Sureau P, Germano P M
Rev Saude Publica. 1989 Dec;23(6):447-54. doi: 10.1590/s0034-89101989000600002.
ERA anti-rabies vaccine prepared in kidney tissue culture was evaluated against four different antigenic strains of rabies virus in mice: two of them dog strains, C/SP and C/NG, another a bat vampire strain, DR-19, and the CVS strain. The CVS antigenic characteristics were determined by means the antinucleocapsid monoclonal antibodies technique. Twenty one days old mice were vaccinated, intramuscularly, in the inner side of the thigh, with 0.05 ml of vaccine and challenged at 42 days old, together with those of the control group, intramuscularly, in the inner side of the thigh, with 0.05 ml of the corresponding viral strain dilution. The ERA anti-rabies vaccine protected 100% of all the mice challenged with C/SP, C/NG and DR-19 strains and 83% of those challenged with CVS. The control groups mortality rate varied between 70 and 90%.
对在肾组织培养中制备的ERA狂犬病疫苗，针对小鼠体内的四种不同狂犬病病毒抗原株进行了评估：其中两种是犬株，C/SP和C/NG，另一种是蝙蝠吸血蝠株，DR - 19，以及CVS株。采用抗核衣壳单克隆抗体技术确定CVS的抗原特性。21日龄小鼠在大腿内侧肌肉注射0.05 ml疫苗，并在42日龄时与对照组一起，在大腿内侧肌肉注射0.05 ml相应病毒株稀释液进行攻毒。ERA狂犬病疫苗保护了所有用C/SP、C/NG和DR - 19株攻毒小鼠的100%以及用CVS攻毒小鼠的83%。对照组的死亡率在70%至90%之间。
